Abstracts tagged "Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)"

Abstract Number: 2380 • ACR Convergence 2023
Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data
Chan-Bum Choi¹, Jung-Min Shin², Nayeon Choi³ and Soorack Ryu³, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea, ³Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare systemic autoimmune disease with varying reports of incidence rates and clinical manifestations. Renal involvement is one of the…
Abstract Number: 0674 • ACR Convergence 2023
Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis
Daiki Sakai¹, Kaichi Kaneko¹, Karin Furukawa², Mai Kawazoe², Yasuo Matsuzawa³ and Toshihiro Nanki², ¹Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ³Division of Respiratory Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, hyper-eosinophilia, and progressive multiorgan organ involvement. Mepolizumab (MPZ) is a humanized monoclonal…
Abstract Number: 0675 • ACR Convergence 2023
Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond
allyson egan¹, Pasupathy Sivasothy² and David Jayne³, ¹Trinity Health Kidney Centre, Tallaght University Hospital, Ireland, Dublin, Ireland, ²Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ³University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
Abstract Number: 0676 • ACR Convergence 2023
Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center
Takashi Yamane¹ and Akira Hashiramoto², ¹Kakogawa Central City Hospital, Kakogawa, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis associated with eosinophil infiltration and Anti-neutrophil cytoplasmic antibody (ANCA) production. Mepolizumab (MPZ), an anti-IL-5 monoclonal…
Abstract Number: 0677 • ACR Convergence 2023
Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan
SOKO KAWASHIMA¹, Yoshinori Komagata¹, Mitsumasa Kishimoto² and Shinya Kaname¹, ¹Kyorin University School of Medicine, Tokyo, Japan, ²Kyorin University School of Medicine, Yokohoma, Japan
Background/Purpose: Contrary to Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan or Asian countries. It is possible that therapeutic responses to EGPA with mepolizumab…
Abstract Number: 0678 • ACR Convergence 2023
Benralizumab in Eosinophilic Granulomatosis with Polyangiitis
Adrien Cottu¹, Matthieu Groh², Charlène Desaintjean³, Sylvain Marchand-Adam⁴, Loic Guillevin⁵, Xavier Puéchal⁶, Estibaliz Lazaro⁷, Maxime Samson⁸, Camille Taillé⁹, Cécile-Audrey Durel¹⁰, Elisabeth Diot¹¹, Sarah Nicolas¹¹, Laurent Guilleminault¹², Mikael Ebbo¹³, Pascal Cathébras¹⁴, Clairelyne Dupin⁹, Halil Yildiz¹⁵, Nabil Belfeki¹⁶, Gregory Pugnet¹⁷, Pierre Chauvin¹⁸, Stephane Jouneau¹⁹, François Lifermann²⁰, Jean-Philippe Martellosio²¹, Vincent Cottin²² and Benjamin Terrier²³, ¹Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, ³Department of Respiratory Diseases, Hôpital Louis Pradel, Lyon, France, ⁴CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, Tours, France, ⁵University Paris Descartes, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁷Bordeaux Hospital University, Pessac, France, ⁸Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ⁹AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, ¹⁰CHU Lyon, Lyon, France, ¹¹Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, ¹²Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, ¹³Aix Marseille Univ, APHM, hôpital de la Timone, Internal Medicine Department, Marseille, France, ¹⁴Department of Internal medicine, Hôpital Nord, CHU St Etienne, Saint-Etienne, France, ¹⁵Saint Luc Hospital, Bruxelles, Belgium, ¹⁶Service de Médecine Interne et Immunologie Clinique. Groupe Hospitalier Sud Île de France, Melun, France, ¹⁷CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ¹⁸Department of Respiratory Diseases, Rennes University Hospital, Rennes, France, ¹⁹Amicus, Boca Raton, FL, ²⁰Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France, ²¹Service de médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France, ²²Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ²³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Gucocorticoid (GC)-dependant asthma and ENT exacerbations may persist in more than 80% of eosinophilic granulomatosis with polyangiitis (EGPA). The MIRRA trial demonstrated the efficacy…
Abstract Number: 0125 • ACR Convergence 2022
Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Initiating Mepolizumab
Jared Silver¹, Arijita Deb², Elizabeth Packnett³, Donna McMorrow³, Cynthia Morrow³ and Michael Bogart¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²GlaxoSmithKline, Upper Providence, PA, ³IBM Watson Health, Cambridge, MA
Background/Purpose: EGPA is a multisystem disorder often characterized clinically by asthma, chronic rhinosinusitis, and prominent eosinophilia, and histopathologically by eosinophil-rich, necrotizing , granulomatous vasculitis of…
Abstract Number: 0432 • ACR Convergence 2022
Predictive Factors of Eosinophilic Granulomatosis with Polyangiitis Long-term Evolution: Data from a European Cohort
Matthias Papo¹, Pauline Martinot², Renato A. Sinico³, Vitor Teixeira⁴, Nils Venhoff⁵, Maria-Letizia Urban⁶, Juliane Mahrhold⁷, Francesco Locatelli⁸, Giulia Cassone⁹, Franco Schiavon¹⁰, Benjamin Seeliger¹¹, Thomas Neumann¹², Claus Kroegel¹³, Matthieu Groh¹⁴, Chiara Marvisi¹⁵, Maxima Samson¹⁶, Thomas Barba¹⁷, David Jayne¹⁸, Arianna Troilo¹⁹, Jens Thiel²⁰, Bernhard Hellmich²¹, Sara Monti²², Carlomaurizio Montecucco⁸, Carlo Salvarani²³, Jean-Emmanuel Kahn²⁴, Cecile-Audrey DUREL²⁵, Luc Mouthon²⁶, Loïc Guillevin²⁶, Giacomo Emmi²⁷, Augusto Vaglio²⁸, Raphaël Porcher²⁹ and Benjamin Terrier²⁶, ¹Service De Médecine Interne - Hôpital Cochin, Paris, France, ²Centre of Research in Epidemiology and Statistics, Université de Paris, Paris, Île-de-France, France, Paris, ³Department of Medicine and Surgery, Università degli Studi di Milano – Bicocca, Italy, Milano, Italy, ⁴Hospital de Faro, CHUA, Lisbon, Portugal, ⁵Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁶Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy, ⁷Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ⁸Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, ⁹Università di Modena e Reggio Emilia, Modena, Italy, ¹⁰Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, ¹¹Department of Respiratory Medicine, Hannover Medical School, Wermsdorf, Germany, ¹²Kantonsspital St. Gallen, St. Gallen, Switzerland, ¹³Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, ¹⁴Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, ¹⁵Università di Modena e Reggio Emilia and National Institute of Arthritis & Musculoskeletal & Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁶Dijon University Hospital, Dijon, France, ¹⁷Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, ¹⁸University of Cambridge, Cambridge, United Kingdom, ¹⁹Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ²⁰University Hospital Freiburg, Freiburg, Germany, ²¹Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, ²²Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ²³Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, ²⁴Service de médecine interne - Hôpital Ambroise Paré, AP-HP, Boulogne-Billancourt, France, ²⁵CHU Lyon, Lyon, France, ²⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²⁷Azienda Ospedaliero Universitaria Careggi, Firenze, Italy, ²⁸Azienda Ospedaliero Universitaria Meyer, Parna, Italy, ²⁹Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Glucocorticoids (GCs) frequently control the…
Abstract Number: 0453 • ACR Convergence 2022
Validation of the 2022 – American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA Associated Vasculitis
Aman Sharma¹, Prateek Deo¹, Shankar Naidu², Joydeep Samanta³, Sakshi Mittal³, Kusum Sharma³, Ritambhra Nada³, Varun Dhir⁴, sanjay jain² and Ranjana Minz², ¹PGIMER, Chandigarh, India, Chandigarh, India, ²Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³PGIMER, Chandigarh, India, ⁴PGIMER, CHD, INDIA, Chandigarh, India
Background/Purpose: The purpose of this study was to validate the recently published 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for…
Abstract Number: 0455 • ACR Convergence 2022
Performance of 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Turkish Vasculitis Patients
Ummugulsum Gazel¹, Sevinc Can Sandikci², Ahmet Omma³, Sinem Burcu Kocaer⁴, Fatoş Onen⁵, Onay Gercik⁶, Servet Akar⁷, Kerem Abacar⁸, Ebru Asicioglu⁹, Serhan Tuglular⁹, Fatma Alibaz-Oner⁸ and Haner Direskeneli¹⁰, ¹University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, ²Ankara Numune Education and Research Hospital, Rheumatology, Ankara, Turkey, ³Ankara Numune Education and Research Hospital, Rheumatology, Ankara, Turkey, Istanbul, Turkey, ⁴Dokuz Eylul University, Faculty of Medicine, Rheumatology, Izmir, Turkey, ⁵Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, ⁶Izmir Tepecik Research Hospital, Izmir, Turkey, ⁷Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁸Marmara University, Rheumatology, Istanbul, Turkey, ⁹Marmara University, Faculty of Medicine, Nephrology, Istanbul, Turkey, ¹⁰Marmara University, Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: The American College of Rheumatology (ACR)-1990 criteria is the most used method for the classification of ANCA Associated Vasculitis (AAV). However, with ACR-1990 criteria,…
Abstract Number: 0457 • ACR Convergence 2022
A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis
Jan Schirmer¹, Beatriz Sanchez-Alamo², Sara Monti³, Bernhard Hellmich⁴, David Jayne⁵ and Gunnar Tomasson⁶, ¹University Medical Center Schleswig-Holstein, Kiel, Germany, ²Lund University, Skåne University Hospital, Lund, Sweden, ³Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ⁴Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Centre for Rheumatology Research, University Hospital Reykjavik, Reykjavik, Iceland
Background/Purpose: Since the publication of the 2016 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV), the publication of…
Abstract Number: 1074 • ACR Convergence 2022
Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis
Berengere Molina¹, Maria Letizia Urban², Roberto Padoan³, Pavel Novikov⁴, Camille Taillé⁵, Marco Caminati⁶, Christine Christides⁷, nicolas schleinitz⁸, Laura Moi⁹, Vincent Cottin¹⁰, bertrand godeau¹¹, Laurence Bouillet¹², Paolo Fraticelli¹³, Ann Knight¹⁴, Jan Walter Schroeder¹⁵, Sylvain Marchand-Adam¹⁶, Helder Gil¹⁷, Elena Gelain¹⁸, Giacomo Emmi² and Benjamin Terrier¹⁹, ¹Department of Internal Medicine, Cochin Hospital, Paris, France, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³University of Padova, Padova, Italy, ⁴Tareev’s Clinic, Sechenov First Moscow State Medical University, Moscow, Russia, ⁵Pulmonology department, Bichat Hospital, Paris, Ile-de-France, France, ⁶Verona University Hospital, University of Verona, Verona, Italy, ⁷Avignon hospital, Avignon, France, ⁸Aix Marseille university, AP-HM, Marseille, France, ⁹Centre hospitalier universitaire vaudois, Lausanne, Lausanne, Switzerland, ¹⁰Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹¹Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Mondor Hospital, Créteil, France, ¹²Grenoble University Hospital, Grenoble, France, ¹³Department of Internal Medicine, Ospedali Riuniti di Ancona, Ancona, Italy, ¹⁴Akademiska sjukhuset, Uppsala, Sweden, ¹⁵ASST GOM Niguarda, Milano, Italy, ¹⁶Tours University Hospital, Tours, France, ¹⁷Besancon University Hospital, Besançon, France, ¹⁸Meyer Children’s University Hospital of Firenze, Florence, Italy, ¹⁹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticosteroids (GCs)-dependent asthma and/or disabling…
Abstract Number: 1075 • ACR Convergence 2022
Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype
Benjamin Terrier¹, David Jayne², Bernhard Hellmich³, Jane Bentley⁴, Jonathan Steinfeld⁵, Steven Yancey⁶, Namhee Kwon⁷, Praveen Akuthota⁸, Paneez Khoury⁹, Lee Baylis¹⁰ and Michael Wechsler¹¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²University of Cambridge, Cambridge, United Kingdom, ³Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, ⁴Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, ⁵Clinical Sciences, Respiratory, GSK (affiliation at time of research), Philadelphia, PA, ⁶Respiratory Therapeutic Area, GSK (affiliation at the time of research), Research Triangle Park, NC, ⁷Clinical Sciences, Respiratory, GSK, Brentford, United Kingdom, ⁸Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California, San Diego, CA, ⁹Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Global Medical Affairs, GlaxoSmithKline, Durham, NC, ¹¹Department of Medicine, National Jewish Health, Denver, CO
Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA) can have vasculitic or eosinophilic phenotypes. The MIRRA study demonstrated that patients with EGPA spent more time…
Abstract Number: 1767 • ACR Convergence 2022
Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
Bernhard Hellmich¹, Konstantin Neukirch², Marco Lukas², Martin Wernitz², Dominik Beier³ and Dennis Häckl⁴, ¹Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ²GlaxoSmithKline GmbH & Co. KG, Munich, Germany, ³InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany, ⁴WIG2 GmbH, Leipzig, Germany
Background/Purpose: EGPA and HES are rare multisystemic diseases associated with eosinophilia. Robust data on the epidemiology and treatment of HES and EGPA are scarce. The…
Abstract Number: L21 • ACR Convergence 2021
Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial
Benjamin Terrier¹, Gregory Pugnet², Claire de Moreuil³, Bernard Bonnotte⁴, Ygal Benhamou⁵, Elisabeth Diot⁶, Dominique Chauveau², Pierre Duffau⁷, Nicolas Limal⁸, Antoine Neel⁹, Geoffrey Urbanski¹⁰, Noemie Jourde-Chiche¹¹, Nicolas Martin-Silva¹², Francois Maurier¹³, Arsene Mekinian¹⁴, Nicolas Schleinitz¹¹, Felix Ackermann¹⁵, Anne-Laure Fauchais¹⁶, Antoine Froissart¹⁷, Thomas Le Gallou¹⁸, Yurdagul Uzunhan¹⁹, Jean-Francois Viallard⁷, Alice Berezne²⁰, Laurent Chiche²¹, Bruno Crestani¹⁴, Guillaume Direz²², Cecile-Audrey Durel²³, Pascal Godmer²⁴, Jean-Emmanuel Kahn²⁵, Marc Lambert²⁶, Thomas Quemeneur²⁷, Jacques Cadranel¹⁴, Pierre Charles²⁸, Antoine Dossier¹⁴, Lea Jilet²⁹, Loic Guillevin¹⁴, Hendy Abdoul²⁹ and Xavier Puechal¹⁴, ¹Cochin Hospital, Paris, France, ²CHU, Toulouse, France, ³CHU, Brest, France, ⁴CHU, Dijon, France, ⁵CHU, Rouen, France, ⁶CHU, Tours, France, ⁷CHU, Bordeaux, France, ⁸CHU, Creteil, France, ⁹CHU, Nantes, France, ¹⁰CHU, Angers, France, ¹¹CHU, Marseille, France, ¹²CHU, Caen, France, ¹³CH, Metz, France, ¹⁴CHU, Paris, France, ¹⁵Hopital Foch, Suresnes, France, ¹⁶CHU, Limoges, France, ¹⁷CHIC, Creteil, France, ¹⁸CHU, Rennes, France, ¹⁹CHU, Bobigny, France, ²⁰CH, Annecy, France, ²¹CH, Marseille, France, ²²CH, Le Mans, France, ²³CHU, Lyon, France, ²⁴CH, Vannes, France, ²⁵CHU, Boulogne, France, ²⁶CHRU, Lille, France, ²⁷CH, Valenciennes, France, ²⁸CH, Paris, France, ²⁹URC, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic ANCA-associated vasculitis.Glucocorticoids, alone or in combination with cyclophosphamide in severe forms, induce remission in most patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].